Cited 0 times in
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이용재 | - |
dc.contributor.author | 이정윤 | - |
dc.date.accessioned | 2021-12-28T16:41:54Z | - |
dc.date.available | 2021-12-28T16:41:54Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186757 | - |
dc.description.abstract | Background: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in BRCA wild-type patients with platinum-sensitive recurrence. We hypothesized that adding pembrolizumab and bevacizumab to olaparib maintenance can increase progression-free survival (PFS) in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer. Methods: BRCA wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab. Forty-four patients will be included from 4 sites across Singapore and Korea. The primary endpoint of the study is 6-month PFS rate. Trial registration: ClinicalTrials.gov Identifier: NCT04361370, Clinical Research Information Service Identifier: KCT0005144. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Asian Society of Gynecologic Oncology : Taehan Puin Chongyang Hakhoe | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Bevacizumab / therapeutic use | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoplasm Recurrence, Local / drug therapy | - |
dc.subject.MESH | Neoplasm Recurrence, Local / genetics | - |
dc.subject.MESH | Ovarian Neoplasms* / drug therapy | - |
dc.subject.MESH | Ovarian Neoplasms* / genetics | - |
dc.subject.MESH | Phthalazines | - |
dc.subject.MESH | Piperazines | - |
dc.subject.MESH | Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use | - |
dc.title | A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Yong Jae Lee | - |
dc.contributor.googleauthor | Myong Cheol Lim | - |
dc.contributor.googleauthor | Byoung Gie Kim | - |
dc.contributor.googleauthor | Natalie Yl Ngoi | - |
dc.contributor.googleauthor | Chel Hun Choi | - |
dc.contributor.googleauthor | Sang Yoon Park | - |
dc.contributor.googleauthor | David Sp Tan | - |
dc.contributor.googleauthor | Yunjung Go | - |
dc.contributor.googleauthor | Jung Yun Lee | - |
dc.identifier.doi | 10.3802/jgo.2021.32.e31 | - |
dc.contributor.localId | A05165 | - |
dc.contributor.localId | A04638 | - |
dc.relation.journalcode | J01428 | - |
dc.identifier.eissn | 2005-0399 | - |
dc.identifier.pmid | 33559413 | - |
dc.subject.keyword | Bevacizumab | - |
dc.subject.keyword | Immunotherapy Recurrence | - |
dc.subject.keyword | Ovarian Neoplasms | - |
dc.subject.keyword | Poly(ADP-ribose) Polymerase Inhibitors | - |
dc.contributor.alternativeName | Lee, Yong Jae | - |
dc.contributor.affiliatedAuthor | 이용재 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.citation.volume | 32 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | e31 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, Vol.32(2) : e31, 2021-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.